SCHEMBL22875089

SCHEMBL22875089

CC(C)C1CCN(C(O)Nc2ccccc2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.43
▸ TDP1 Q9NUW8 2/20 0.40
▸ ACHE P22303 2/20 0.40
▸ EPHX2 P34913 1/20 0.38
▸ KDM1A O60341 1/20 0.38
▸ OPRL1 P41146 2/20 0.37
▸ CARM1 Q86X55 1/20 0.37
▸ PRMT6 Q96LA8 1/20 0.37
▸ LMNA P02545 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ ALOX12 P18054 1/20 0.36
▸ RECQL P46063 1/20 0.36
▸ ATM Q13315 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ HRH3 Q9Y5N1 1/20 0.36
▸ CTSL P07711 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8252470 0.76 NPY2R (0.53) ALDH1A1TDP1
SCHEMBL22874976 0.76 CYP2D6 (0.44) ACHECARM1PRMT6LMNACYP3A4
SCHEMBL31053471 0.73 ACHE (0.43) ALDH1A1TDP1ACHEEPHX2OPRL1
SCHEMBL22875083 0.72 LMNA (0.46) TDP1ACHELMNACYP3A4TSHR
SCHEMBL8252174 0.71 ALDH1A1 (0.63) ALDH1A1TDP1LMNATSHR
SCHEMBL25442295 0.70 CCR1 (0.49) ALDH1A1EPHX2LMNATSHRCTSL
SCHEMBL23903537 0.70 CCR1 (0.50) ALDH1A1CTSLCTSBCTSK
SCHEMBL25442301 0.70 CASP3 (0.40) ALDH1A1TDP1ACHEEPHX2LMNA
SCHEMBL25442293 0.70 CCR1 (0.49) ALDH1A1EPHX2LMNATSHRCTSL
SCHEMBL22875267 0.70 GRIN2B (0.43) ACHELMNACYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753397-B2 Cereblon binders for the degradation of ikaros C4 THERAPEUTICS, INC. (US) 2023-09-12 — — US disclosed
US-20210009559-A1 CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS C4 THERAPEUTICS, INC. (US) 2021-01-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753397-B2 Cereblon binders for the degradation of ikaros CRBN, IKZF1, IKZF3 ALDH1A1 3363/4885TDP1 3415/4885ACHE 3575/4885
US-20210009559-A1 CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS CRBN, IKZF1, IKZF3 ALDH1A1 4009/4885TDP1 3104/4885ACHE 2387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback